» Articles » PMID: 38543094

Galactose: A Versatile Vector Unveiling the Potentials in Drug Delivery, Diagnostics, and Theranostics

Overview
Publisher MDPI
Specialty Chemistry
Date 2024 Mar 28
PMID 38543094
Authors
Affiliations
Soon will be listed here.
Abstract

D-galactose, a simple natural compound, has been investigated as a powerful scaffold for drug delivery, diagnostics, and theranostics due to its distinctive properties and interactions with specific cell receptors. In the field of drug delivery, galactose functions as a ligand to selectively target cells expressing galactose receptors, such as hepatocytes, macrophages, and specific cancer cells. The direct attachment of galactose to the main drug or to drug-loaded nanoparticles or liposomes enhances cellular uptake, thereby improving drug delivery to the intended target cells. Galactose has also been found to be useful in diagnostics. Specifically, diagnostic tests based on galactose, such as the galactose elimination capacity test, are utilized to evaluate liver function and assess liver disease as well as hepatic functional reserve. Additionally, galactose-based theranostic agents can be designed by combining drug delivery and diagnostic capabilities. This review is an update of our previous review concerning the broad spectrum of possibilities for exploiting D-galactose as a vector for prodrug design and the synthetic strategies that allow its realization, jointly in diagnostics and theranostics, to highlight the versatility of this interesting vector.

Citing Articles

Analysis of Population Structure and Selective Signatures for Milk Production Traits in Xinjiang Brown Cattle and Chinese Simmental Cattle.

Ma K, Li X, Ma S, Zhang M, Wang D, Xu L Int J Mol Sci. 2025; 26(5).

PMID: 40076627 PMC: 11900343. DOI: 10.3390/ijms26052003.


Advances in acid-degradable and enzyme-cleavable linkers for drug delivery.

Zhao S, Yu N, Han H, Guo S, Murthy N Curr Opin Chem Biol. 2024; 84:102552.

PMID: 39642424 PMC: 11788058. DOI: 10.1016/j.cbpa.2024.102552.

References
1.
Dang Y, Ruan L, Tian Y, Xu Z, Zhang W . Nitric Oxide Prodrug Delivery and Release Monitoring Based on a Galactose-Modified Multifunctional Nanoprobe. Anal Chem. 2021; 93(21):7625-7634. DOI: 10.1021/acs.analchem.1c00287. View

2.
Hu H, Xiao C, Wu H, Li Y, Zhou Q, Tang Y . Nanocolloidosomes with Selective Drug Release for Active Tumor-Targeted Imaging-Guided Photothermal/Chemo Combination Therapy. ACS Appl Mater Interfaces. 2017; 9(48):42225-42238. DOI: 10.1021/acsami.7b14796. View

3.
Zhang J, Song H, Ji S, Wang X, Huang P, Zhang C . NO prodrug-conjugated, self-assembled, pH-responsive and galactose receptor targeted nanoparticles for co-delivery of nitric oxide and doxorubicin. Nanoscale. 2018; 10(9):4179-4188. DOI: 10.1039/c7nr08176f. View

4.
Boger D, Johnson D . CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. Proc Natl Acad Sci U S A. 1995; 92(9):3642-9. PMC: 42018. DOI: 10.1073/pnas.92.9.3642. View

5.
Zhang F, Magruder J, Lin Y, Crawford T, Grimm J, Sciortino C . Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model. J Control Release. 2017; 249:173-182. PMC: 5323327. DOI: 10.1016/j.jconrel.2017.01.032. View